08:30-09:30 Registration and light breakfast
09:30-09:40 Welcome and Introduction
09:45-10:15 Key note: Olli Kallioniemi: Data- and AI-driven life science: Foundational models and hallmarks for cancer
Session 1: Spatial profiling (Chair: Teijo Pellinen)
10:15-10:45 Antti Kiviaho: An integrative analysis approach to spatial transcriptomics of prostate tumors
10:45-11:00 Andrew Erickson: Spatial genomics prostate cancer
11:00-11:15 Anna Laury: Spatial profiling of Ovarian carcinoma
11:15-11:30 Company presentation: Akoya Biosciences
11:30-12:30 LUNCH
Session 2: AI pathology (Chair: Patrick Micke)
12:45-13:00 Pekka Ruusuvuori: Generalization gap in histopathology AI
13:00-13:15 Sampsa Hautaniemi: Instance and semantic segmentation of H&E images in ovarian cancer
13:15-13:30 Tuomas Mirtti: Controllable and explainable AI in clinical pathology
13:30-13:45 Mikko Purhonen: Prediction of Treatment-free Remission with Convolutional Neural Network-guided Image Analysis in CML
13:45-14:00 Company presentation: Miltenyi Biotech
14:00-14:10 Company presentation: Aiforia
14:15-15:15 COFFEE & POSTERS (Kullager)
Session 3: Heterogeneity (Chair: Olli Carpén)
15:15-15:30 Steve Bova: Pilot 3D prostate cancer metastatic and nonmetastatic subclone tracking and timing
15:30-15:45 Rolf Skotheim: Challenges and opportunities in managing the extensive heterogeneity of multifocal prostate cancer
15:45-16:00 Martin Johansson: Kidney disease and regeneration
16:00-16:15 Pekka Taimen: Steroid hormone landscape of bladder cancer
16:15-16:25 Company presentation: Standard Biotools, David Guet
16:30-18:00 POSTERS and REFRESHMENTS (Kullager)
18:00-19:30 Activities (Jogging/Gym/Art exhibition/Sauna+pool)
19:30 SPARKLING
20:00 DINNER
08:30-09:00 Coffee
Session 4: Tumor microenvironment (Chair: Caj Haglund)
09:00-09:15 Linglong Huang: Novel colon cancer multi-marker-defined fibroblast subsets; associations with micro-niches and survival
09:15-0930 Maria Ulvmar: Analysis of structural vascular and stromal changes in tumor draining lymph nodes
09:30-09:45 Jaakko Knuutila: CAFs in squamous cell carcinoma of the skin
09:45-10:00 Sanna Pasonen-Seppänen: Dynamic interplay between macrophages and melanoma cells in tumor microenvironment
10:00-10:15 Karolina Punovuori: Role of tissue architecture and cell communication in cancer progression
10:15-10:30 Lassi Paavolainen: Unsupervised multiplexed spatial profiling of CAFs
10:30-11:00 COFFEE & CROSSTALK
Session 5: Biomarkers (Chair: Arne Östman)
11:00-11:15 Patrick Micke: Novel strategies to understand cancer immunity and its therapeutic impact
11:15-11:30 Caroline Schagerholm: Gene expression profiles in endocrine-resistant breast cancer
11:30-11:45 Camilla Böckelman: Molecular subtypes in gastrointestinal cancers
11:45-12:00 Kari Alitalo: A proxy for stem cells and tumor progression in colorectal cancer
12:00-12:15 Sami Ventelä: Biomarker for identification of HNSCC patients in risk of developing metastastic disease
12:15-13:30 LUNCH (CHECK-OUT TIME IS 12:00)
Session 6: Functional models and perturbation (Chair: Carina Strell)
13:30-13:45 Xinsong Chen: Breast Cancer Precision Medicine Assisted by Functional Assays And Multi-omics Data
13:45-14:00 Ashwini Nagaraj: Precision oncology for ovarian cancer using patient-derived immunocompetent cultures
14:00-14:15 Kirsi Ketola: Overcoming drug resistance in prostate cancer
14:15-14:30 Margarita Espona-Fiedler: From drug discovery to Onco-fibrotherapy
14:30-14:45 Heidi Haikala: Modeling solid tumor complexity and vascularity using organ-on-a-chip
14:45-15:00 Vesa Rahkama: High Fidelity Physiological Culture System for Prostate Cancer
15:00-15:15 Closing remarks
| Name | Title |
| 1. Pauliina Munne | Patient Derived Explant Cultures (PDEC) as a Model for Treatment Resistant ERα Positive Breast Cancer |
| 2. Oxana Denisova | Protein phosphatase PP2A-based triple-strike therapy for medulloblastoma |
| 3. Rasmus Humlevik | Hypoxia and immune evasion in young women with breast cancer: a population-based study |
| 4. Viktor Ljungström | Single-cell gene expression analysis of normal tissues for discovery of mechanisms of permissiveness for KRAS mutations |
| 5. Laura Sysivirta | Spatial Concordance Between Genome and Proteome in Oncology: A Systematic Review |
| 6. Reetta Nätkin | Phenotypic and genotypic characterisation of bicalutamide and enzalutamide resistance in castration-resistant prostate cancer cells |
| 7. Silje Kjølle | Basal-like breast cancer secretomes induce angiogenic signaling in the tumor microenvironment |
| 8. Anna Gerdtsson | Spatial tumor-immune protein signatures across subtypes of ovarian carcinoma |
| 9. Jenni Säilä | FAP/αSMA association with tumor MRI-visibility and progression in prostate cancer |
| 10. Jussi Kasurinen | Phenotypic subtypes predict outcomes in colorectal cancer |
| 11. Carina Strell | Effect of beta-blockers in patients with ductal carcinoma in situ on the risk of invasive breast cancer recurrence: a retrospective cohort study |
| 12. Ella Kesti | The prognostic significance of collagen VI in pancreatic ductal adenocarcinoma |
| 13. Jefim Brodkin | Prognostic effect of immunohistochemically classified molecular subtypes in gastric cancer |
| 14. Sonja Koivukoski | Unstained tissue imaging and virtual HE-staining of histological whole slide images: an assessment of histological feasibility |
| 15. Margarita Espona-Fiedler | High throughput screen in a pancreatic tumor-stroma model: uncovering therapeutic strategies |
| 16. Linglong Huang | Identification of spatially localized and prognosis-associated multi-marker-defined mesenchymal cell subsets of human colon cancer |
| 17. Annabrita Schoonenberg | FIMM Digital Microscopy and Molecular Pathology Unit |
| 18. Anette Holmström | Spatial transcriptomics services in FIMM Single-Cell Analytics Unit |
| 19. Teijo Pellinen | Spatial profiling of inflamed clear-cell renal cell carcinoma tumor microenvironment |
| 20. Astrid Murumägi | Targeting interacting pathways between cancer cells and fibroblasts in prostate cancer |
| 21. Vesa Rahkama | High Fidelity Physiological Culture System for Prostate Cancer |
| 22. Katja-Rikka Louhi | SignalStar™ multiplex immunohistochemistry is a flexible technology with fully validated protocols |
| 23. Amanda Lindberg | Investigation of PD1-PDL1 interaction as a predictor for response to immune checkpoint therapy in NSCLC patients |
| 24. Hui Yu | FGFR2 splice variant as a cell fate adjudicator determines clinical outcomes in NSCLC |
| 25. Artemis Filippou | Liprin-a1 contributes to oncogenic MAPK signaling and associates with MEK/ERK inhibitor response |
| 26. Maria Ulvmar | Evaluation of vascular and stromal changes in tumor draining lymph nodes of patients with pancreatic cancer using AI-driven image analysis - new potential sources of biomarkers in cancer |
| 27. Robert Stad | Akoya Biosciences |
| 28. Anni Sjöblom | NOVEL BIOMARKERS IN THE MANAGEMENT OF OROPHARYNGEAL SQUAMOUS CELL CARCINOMA |